NeuroNascent: Neuronascent Announces Publication of Pre-clinical Results of Alzheimer's Disease Clinical Candidate, NNI-362 in SCR&T Journal

(marketscreener.com) CLARKSVILLE, Md., Jan. 20, 2021 -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically stimulate neural regeneration in human cultures and in vivo models of aging and disease. This small molecule therapy is...https://www.marketscreener.com/news/latest/Neuronascent-Announces-Publication-of-Pre-clinical-Results-of-Alzheimer-s-Disease-Clinical-Candidate--32235102/?utm_medium=RSS&utm_content=20210120